June 2016 ACIP Immunization Update
|
|
- Melvyn Carson
- 5 years ago
- Views:
Transcription
1 June 2016 ACIP Immunization Update Stephan L. Foster, PharmD, FAPhA CAPT (Ret) USPHS Professor, University of Tennessee College of Pharmacy Liaison Member, CDC Advisory Committee on Immunization Practices (ACIP) Disclosures Stephan L. Foster, PharmD, FAPhA, serves on speakers bureaus for Merck, Pfizer, and Sanofi Pasteur; he is also on the advisory boards for Seqirus and Pfizer. APhA s editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For complete staff disclosures, visit Conflicts of interest have been resolved through content review by Helen Sairany, PharmD, BCACP, Associate Director of Content Development at the American Pharmacists Association. Accreditation Information The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (CPE). This activity, June 2016 ACIP Immunization Update HOME STUDY, is approved for 1 hour of CPE credit (0.10 CEUs). The ACPE Universal Activity Numbers assigned by the accredited provider are: H04-P (pharmacists) H04-T (pharmacy technicians) To obtain CPE credit for this activity, participants are required to complete the assessment and evaluation questions by July 27, Initial Release Date: August 10, 2016 Target Audience: Pharmacists and pharmacy technicians Activity Type: Knowledge-based Learning Level: 2 Fee: There is no fee for this activity by the American Pharmacists Association. All rights reserved. 1
2 Development This recording of the July 27 webinar entitled, June 2016 ACIP Immunization Update, is an online continuing education activity for pharmacists and pharmacy technicians developed by the American Pharmacists Association. Learning Objectives At the completion of this knowledge-based activity, participants will be able to: Identify how the proposed changes to vaccine recommendations will impact the immunization schedules for children, adolescents, and adults Explain how recent changes to vaccine recommendations will impact their vaccination programs Discuss information on new or future vaccines for potential use in their practices Self-Assessment Question #1 The FDA has approved meningococcal B vaccination with Trumenba: A. As single dose B. As a 2-dose series given at 0 and 1-2 months under certain circumstances C. As a 2-dose series given at 0 and 6 months under certain circumstances D. That must always be given as a 3-dose series at 0, 1-2 months, and 6 months 2016 by the American Pharmacists Association. All rights reserved. 2
3 Self-Assessment Question #2 The ACIP has recommended that vaccination with LAIV (FluMist) in the influenza season: A. Is preferred in children over IIV B. Has no preference from the ACIP over IIV C. Should not be given to anyone D. Should be given to all age-eligible patients, aged 2-49 years Self-Assessment Question #3 The ACIP is discussing vaccination with a 2-dose series of HPV9 in a 0-6 month schedule for: A. Patients aged years B. Patients aged 9-14 years C. Patients aged years D. Is not recommended for any age June 2016 ACIP Immunization Update 2016 by the American Pharmacists Association. All rights reserved. 3
4 Dr. Thomas Frieden, Director, CDC Cholera Vibrio cholerae Type O1 (99% of global infections) Type O139 Rare in U.S. Most are in travelers Watery diarrhea Can be severe or fatal Endemic in over 50 countries Treatment rehydration Prevention Safe food and water Personal hygiene High Risk Travelers Visiting friends and relatives Long-term Not following safe water, food, personal hygiene Healthcare workers and response workers Populations at risk for poor outcomes No access to rehydration or medical care Conditions Blood type O (cholera gravis) Pregnancy Immune deficiency CV or renal disease Low gastric acidity 2016 by the American Pharmacists Association. All rights reserved. 4
5 Vaxchora (CVD 103-HgR) PaxVax Hamilton, Bermuda FDA approved June 10, 2016 Fast tracked and priority review Live-attenuated, oral Not absorbed Several different formulations have been tried Redeveloped as Vaxchora Efficacy based upon immunogenicity and oral cholera challenge One Study 90% efficacy at 10 days and 80% at 3 months Vaxchora Single oral dose given 10 days before travel Approved for persons aged years Adverse effects Tiredness, headache, abdominal pain, N/V, lack of appetite, diarrhea No data on this vaccine Pregnancy, breastfeeding, immunocompromised, children, shedding/household transmission Limited data on older formulations No effectiveness data Persons living in cholera areas Persons with pre-existing immunity to cholera Vaxchora Does not protect against other strains of cholera Duration of protection No efficacy data beyond 3 to 6 months Seroconversion studies up to 6 months (90.4%) No revaccination studies 2016 by the American Pharmacists Association. All rights reserved. 5
6 ACIP Recommendation Safe food and water precautions Evaluation of risk of infection for everyone Not recommended for travelers at low risk of exposure Consider risk factors Recommended: Travelers to areas of active cholera transmission Meningococcal B Vaccine Revised dose schedule for Trumenba (Pfizer) approved by FDA (April 4, 2016) 0, 6 months 0, 1-2, 6 months Choice depends upon risk of exposure and patient s susceptibility to MenB disease Based upon reanalysis of earlier studies used for initial approval Current ACIP Recommendations Persons aged >10 years who are at increased risk for meningococcal disease should receive MenB vaccine (Category A) MenB series may be administered to adolescents and young adults aged years to provide short-term protection against most strains of serogroup B meningococcal disease (Category B) 2016 by the American Pharmacists Association. All rights reserved. 6
7 Meningococcal Vaccines in U.S. Men ACWY Vaccines Menomune Sanofi Pasteur (MPSV4) Menactra Sanofi Pasteur (MenACYW135-D) Menveo Novartis (MenACYW-135-CRM) MenHibrix GSK (HibMenCY-TT) CDC-ACIP recommendations Routine in adolescents High-risk >2 months of age MenB Vaccines Both licensed by FDA for persons aged years Trumenba (Pfizer) 3-dose series (0, 2, 6 months) Components: fhbp subfamily A/v2,3; subfamily B/v1 Bexsero (Novartis) 2-dose series (0, 1 6 months) Components: fhbp subfamily B/v1, NhbA, NadA, Por A1.4 ACIP, October 30, 2014 ( Trumenba Dosing Schedules Studied 3-dose schedule 0,2,6 months 0,1,6 months 2-dose schedule 0-6 months 0-4 months 0-2 months 0-1 month 2016 by the American Pharmacists Association. All rights reserved. 7
8 Percentage with >4-fold Increase in hsba Titer (From PI) Trumenba 3-dose (0,1,6 months) % Composite Response 80.3% 3-dose (0,2,6 months) % Composite Response 81.8% 2-dose (0,6 months) % Composite response 72.9% Bexsero (0,1 month) Composite response 63-88% (2 studies) Workgroup Conclusions 2-dose series Best schedule is 0-6 months Lower hsba titers than 3 dose GMTs are lower compared with 3 dose Data not presented Antibody persistence not presented Will be in October No safety issues Issues to discuss hsba data for outbreaks Impact on carriage Discussion Workgroup prefers 3 dose for persons at increased risk (including outbreaks) Workgroup prefers 3 dose for adolescents Maximizes protection Both schedules require 3 months to complete Perhaps if someone receives first dose and returns for second at 6 months, then consider only 2 doses Committee wants more data No vote More to come Possible vote October 2016 Start discussing booster doses next year 2016 by the American Pharmacists Association. All rights reserved. 8
9 MenACYW-135 The risk of meningococcal disease increases in patients with HIV Vaccination not currently recommended in U.S. $732,000/QALY estimated $212,000/QALY for vaccinating all adolescents Grade analysis showed evidence of benefit was low Seroresponse in persons aged 2-10 years with HIV is low and rapidly wanes Deliberations Only MenACYW, Not MenB Increased risk is lifelong in HIV patients Booster doses would be needed Suggests adding HIV to high-risk group Differing opinion on age of vaccination 2 months vs 11 years Small numbers, aligns with asplenia recommendation Vote Passed Human Immunodeficiency Virus (HIV)-infected persons aged >2 months should routinely receive MenACYW vaccine Hepatitis Vaccines Recommendations old Hepatitis A 2006 Hepatitis B 2005 and 2006 Changes since Twinrix Hepatitis B in DM Post-exposure management for HCP Hepatitis B infected mothers Workgroup to start working on new recommendations 2016 by the American Pharmacists Association. All rights reserved. 9
10 FluLaval Quadrivalent (GSK) FDA approved August 2013 for ages >3 years Submitted Biologics License Application to include ages 6-35 months Expect FDA response November 2016 Utilize same dose (15 mcg each strain) Currently Fluzone only vaccine available for this age group 7.5 mcg each strain Other vaccines not studied or too reactogenic Safety and immunogenicity similar to Fluzone More discussion in future meetings Flucelvax Quadrivalent (Seqirus) FDA approved May 23, 2016 for persons aged >4 years Prepared in canine kidney cells Safety and efficacy Immunogenicity non-inferior to cciiv3 Similar safety profile Vaccine Safety Monitoring Influenza Season VAERS No safety concerns Will add new vaccines for next review Guillain-Barré syndrome (GBS) FDA real-time monitoring with CMS of Medicare patients 7.25 cases/million reported (15.4 million doses given) 5.45 cases/million for past 3 seasons Vaccine Safety Datalink (VSD) Relative Risk (RR) (3.1 million doses) RR last year 2.6 additional GBS cases per million doses Similar to some previous seasons Change from ICD-9 to ICD-10 limited data available 2016 by the American Pharmacists Association. All rights reserved. 10
11 2016 by the American Pharmacists Association. All rights reserved. 11
12 Vaccine Effectiveness U.S. Flu VE Network All Ages Any Vaccine Overall Adjusted VE 47% A/H1N1pdm09 41% A/H3N2 45% B/Yamagata 55% B/Victoria 55% IIV Overall Adjusted VE 49% A/H1N1pdm09 44% A/H3N2 43% B/Yamagata 59% B/Victoria 58% Vaccine Effectiveness Ages 2-17 Any Virus A/H1N1pdm01 B-Yamagata B-Victoria IIV LAIV Ages 2-8 Any Virus A/H1N1pdm01 B IIV LAIV Ages 9-17 Any Virus A/H1N1pdm01 B IIV LAIV by the American Pharmacists Association. All rights reserved. 12
13 Vaccine Effectiveness DOD Military Dependents Aged 2-17 years Any Virus A/H1N1pdm01 A/H3N2 All B IIV LAIV AstraZeneca ICICLE Study Ages 2-17 years Any Virus A/H1N1pdm01 All B IIV LAIV AstraZeneca Other studies presented Finland National Institute for Health and Welfare Comparison throughout season Comparison over years Conclusions No explanation for differences ICICLE and Finland studies showed good VE Limitations of observational study designs Sample size limitations Results of VE since years (U.S. Flu Network) Any Flu A or B Mixed H3N H3N H1N H3N H1N2 IIV LAIV LAIV DOD 18 years+ Any Flu A or B Mixed H3N H3N2 IIV LAIV LAIV H1N by the American Pharmacists Association. All rights reserved. 13
14 Possible Explanations Suboptimal performance of A/H1N1 vaccine strain Interference among virus when additional B strain added to quadrivalent Reduce immunogenicity of LAIV as a result of more highly vaccinated population in later years; more children were vaccine naïve in earlier years Recommendations for LAIV Potential Issues Decreased effectiveness against A/H1N1pdm09 Unknown effectiveness against A/H3N2 and B Possible shortages Impact on school programs No alternative for those who refuse injections Communication difficulties How to predict effectiveness in future seasons if not used Vote In light of the evidence for poor effectiveness of LAIV in the United States over the last three influenza seasons ( ), for the season, the ACIP makes the interim recommendation that LAIV should not be used. Recommendations for Influenza Season No LAIV Reiteration of vaccination of all persons 6 months and older Minor change in wording of vaccination timing Healthcare providers should offer vaccination by October, if possible. Vaccination should continue to be offered as long as influenza viruses are circulating. Changes to egg allergy recommendations New vaccines 2016 by the American Pharmacists Association. All rights reserved. 14
15 Respiratory Syncytial Virus (RSV) Humans only source Spread by direct or close contact Incubation 4-6 days Viral shedding 3-8 days (up to 4 weeks) Major cause of lower respiratory disease Infants and children 50% infected in 1 st year of life 150,000 hospitalizations/year Bronchiolitis, pneumonia, or apnea Adults Substantial outpatient burden Repeated yearly infections Most upper respiratory worse than common cold 177,000 hospitalizations of persons aged 65 years and older 14,000 deaths yearly RSV Vaccine No vaccine over last 59 years since virus discovery Monoclonal antibodies for high-risk infants First vaccine 1966 Formalin Inactivated More severe RSV disease than unvaccinated Infants need replicating vaccine Subunit vaccines (+ adjuvants for adults) RSV Vaccine Needs Neonates Maternal antibodies prevent live vaccines Older infants and children Live-attenuated vaccines (Phase 1 trials) Pregnant women Transfer of maternal antibodies Prevent infection from mother to infant Subunit vaccines (Phase 1-3 trials) Older adults Subunit inactivated vaccines RSV F subunit nanoparticle vaccine first before FDA ACIP to consider over next 2 years 2016 by the American Pharmacists Association. All rights reserved. 15
16 Tdap in Pregnant Women Current recommendations weeks New data on 2 nd trimester and weeks Higher maternal antibody concentrations Higher pertussis toxin in mothers early No apparent differences in neonatal titers More to discuss at October ACIP meeting Safety monitoring No increase in birth defects More injection site reactions but still within expected rates Laboratory Confinement of Poliovirus Last cases WPV2 October 1999 India WPV3 November 2012 Nigeria WPV (16 cases) 11 Pakistan 5 Afghanistan WHO Action Plan Containment Destroy Transfer to Essential Laboratory Contain become an Essential Laboratory U.S. Action Plan National survey Last done in Completion of survey July 31, 2016 Containment Phase 1 WPV2 Completion 2016 Phase 2 all WPV Completion 2019 Many challenges Labs concerned about future research Academic labs with frequent turnover Some labs unaware of containment Absolute containment not possible Excretion of virus Synthetic biology production possible 2016 by the American Pharmacists Association. All rights reserved. 16
17 HPV Vaccine Application to FDA Merck 2-dose schedule HPV9 WHO recommended for HPV2 and HPV4 Administered before age 15 years Immunogenicity data presented at February ACIP Higher titers with vaccination than natural infections Non-inferior antibody response in 9-14 year olds Compared with 3 doses in year olds 0 6 months or 0 12 months schedule Higher seroconversion in younger ages HPV2 (GSK) to withdraw from U.S. November 2016 HPV4 (Merck) to withdraw by end of Dose Schedules Persistence No evidence of waning antibodies after 3 dose HPV2 and HPV4 10 years (some studies ongoing) Immune memory demonstrated by anamnestic response to additional doses No data from 2-dose studies Cost effectiveness Many factors (efficacy, increased coverage) Must protect at least 20 years 2-Dose Schedules Review of studies in other countries No studies of HPV9 13 studies reviewed 3 post-hoc analyses of clinical trials Similar outcomes of 3-dose series 10 evaluating uncompleted series Most looked at 0-1 month or 0-2 month 0-6 months showed good effectiveness data Post-licensure effectiveness studies have many issues GRADE Analysis Compare ages 9-14 years with years Non-inferior immunogenicity Decreased adverse effects 2016 by the American Pharmacists Association. All rights reserved. 17
18 Draft Proposal 2-dose schedule at age years Second dose 6-12 months after first If interval less than 6 months, give 3rd dose 6 months from first 3-dose schedule after 15th birthday 0,1-2,6 months Immunocompromised 3-dose series Discuss again at October Meeting Summary and Conclusions Next ACIP Meeting October 19-20, 2016 in Atlanta If questions, please contact: Stephan L. Foster, PharmD sfoster@uthsc.edu Reminder ACIP recommendations are not final. The director of the CDC makes the final decision. Not official until published in MMWR. Do not incorporate these discussions/decisions into practice until published by the American Pharmacists Association. All rights reserved. 18
19 Self-Assessment Question #1 The FDA has approved meningococcal B vaccination with Trumenba: A. As a single dose B. As a 2-dose series given at 0 and 1-2 months under certain circumstances C. As a 2-dose series given at 0 and 6 months under certain circumstances D. That must always be given as a 3-dose series at 0, 1-2 months, and 6 months Self-Assessment Question #2 The ACIP has recommended that vaccination with LAIV (FluMist) in the influenza season: A. Is preferred in children over IIV B. Has no preference from the ACIP over IIV C. Should not be given to anyone D. Should be given to all age eligible patients aged 2-49 years Self-Assessment Question #3 The ACIP is discussing vaccination with a 2-dose series of HPV9 in a 0-6 month schedule for: A. Patients aged years B. Patients aged 9-14 years C. Patients aged years D. Is not recommended for any age 2016 by the American Pharmacists Association. All rights reserved. 19
20 AUDIENCE QUESTIONS How to Obtain CPE Credit (Webinar) 1. At the conclusion of this activity, log in to pharmacist.com 2. Click LEARN, MY TRAINING. Under ENROLLMENTS, click on activity, June 2016 ACIP Immunization Update 3. Complete assessment and evaluation questions 4. Claim credit Deadline to claim credit for this online activity is July 27, No credit will be issued after this date. ACPE Universal Activity Numbers to claim credit: H04-P (pharmacists) H04-T (pharmacy technicians) APhA members may claim CPE credit for either the live webinar or home-study (webinar recording); you may not claim credit for both. A supplemental clinical case challenge will become available after participants have completed either live webinar OR home-study by the American Pharmacists Association. All rights reserved. 20
Hemagglutinin Neuraminidase
Evolving Vaccine Guidance: Influenza, Meningococcal & HPV Vaccines H. Cody Meissner, M.D. Professor of Pediatrics Tufts University School of Medicine Maine Chapter AAP Bar Harbor, Maine October 16, 2016
More informationImmunization Update 2017 Adult Clinical Learning Day. Tamara Sheffield, MD, MPA, MPH
Immunization Update 2017 Adult Clinical Learning Day Tamara Sheffield, MD, MPA, MPH Highlighted Topics Influenza Vaccine Errors 2 Dose HPV Community protection Tdap in pregnancy Meningococcal Future Recs
More informationWHAT S NEW WITH VACCINATIONS IN 2016?
WHAT S NEW WITH VACCINATIONS IN 2016? MenB and a Few Other Changes Lynn Bahta, RN, PHN Immunization Clinical Consultant Minnesota Department of Health May 2016 Disclosure No conflict of interest Will discuss
More informationImmunization Update Tamara Sheffield, MD, MPA, MPH
Immunization Update 2015 Tamara Sheffield, MD, MPA, MPH Disclosure I do not have any relevant financial relationships with any commercial interests I am a Medical Director employed by Intermountain Healthcare
More informationHot off the press, What s new for immunizations in 2017?
Hot off the press, What s new for immunizations in 2017? Jennifer Girotto, PharmD, BCPPS Faculty Disclosure Dr. Girotto has no actual or potential conflicts of interest associated with this presentation.
More informationImmunization Update 2017 Peds Clinical Learning Day. Tamara Sheffield, MD, MPA, MPH
Immunization Update 2017 Peds Clinical Learning Day Tamara Sheffield, MD, MPA, MPH Highlighted Topics Influenza Vaccine Errors 2 Dose HPV Community protection Tdap in pregnancy Hepatitis B Meningococcal
More information2017 Immunization Update for Pharmacy Professionals
2017 Immunization Update for Pharmacy Professionals North Suburban Pharmacists of Chicagoland CPE Program May 3, 2017 Lauren B. Angelo, PharmD, MBA Associate Professor Rosalind Franklin University of Medicine
More informationImmunization Update Disclosures. Candice Robinson, MD, MPH Medical Officer Immunization Services Division 5/12/2017
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Immunization Update 2017 Candice Robinson, MD, MPH Medical Officer Immunization Services Division Western
More information2017 Vaccination Update
2017 Vaccination Update NATHAN BOONSTRA, MD General Pediatrician, Blank Pediatric Clinic TODAY S OBJECTIVES Review the latest recommendations for immunizations, including HPV Meningococcal vaccines Influenza
More informationVACCINES-WHAT HAS HAPPENED IN THE LAST YEAR. Mark H. Sawyer UCSD School of Medicine Rady Children s Hospital San Diego
VACCINES-WHAT HAS HAPPENED IN THE LAST YEAR Mark H. Sawyer UCSD School of Medicine Rady Children s Hospital San Diego LOTS HAS HAPPENED AND IT CAN BE A LITTLE CONFUSING Some people can get 2 doses of HPV
More informationAndrew Kroger, MD, MPH National Center for Immunization and Respiratory Diseases MCH & Immunization Conference Anchorage, AK September 28, 2010
2010 Immunization Update Andrew Kroger, MD, MPH National Center for Immunization and Respiratory Diseases MCH & Immunization Conference Anchorage, AK September 28, 2010 Disclosures No financial conflict
More informationImmunization Update 2016 Clinical Learning Day. Tamara Sheffield, MD, MPA, MPH
Immunization Update 2016 Clinical Learning Day Tamara Sheffield, MD, MPA, MPH Disclosure I do not have any relevant financial relationships with any commercial interests I am a Medical Director employed
More informationNeedle Facts: Immunization Update 2017
Needle Facts: Immunization Update 2017 Miranda Wilhelm, Pharm.D. Clinical Associate Professor Southern Illinois University Edwardsville (SIUE) School of Pharmacy Disclosure and Conflict of Interest Miranda
More informationImmunization Update. William Atkinson, MD, MPH. Immunization Action Coalition
Immunization Update William Atkinson, MD, MPH Immunization Action Coalition Coordinated School Health Conference Lake Ozark, Missouri December 3, 2016 1 Disclosures William Atkinson has no financial relationships
More informationVaccines for infants- What has happened in the last year?
Vaccines for infants- What has happened in the last year? MARK H. SAWYER UCSD SCHOOL OF MEDICINE RADY CHILDREN S HOSPITAL SAN DIEGO Lots has happened and it can be a little confusing Infants used to require
More informationNeedle Facts: Immunization Update Mirada Wilhelm, PharmD Clinical Associate Professor SIUE School of Pharmacy
Needle Facts: Immunization Update 2015 Mirada Wilhelm, PharmD Clinical Associate Professor SIUE School of Pharmacy Objectives Pharmacists At the conclusion of this program, the pharmacist will be able
More informationImmunization Update: New CDC Recommendations. Blaise L. Congeni M.D. 2012
Immunization Update: New CDC Recommendations Blaise L. Congeni M.D. 2012 Polysaccharide Vaccines Vaccine Hib capsule polysaccharide PRP (polyribose ribitol phosphate) Not protective in infants
More informationUPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES
DISCLOSURES UPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES Nothing to disclose Kylie Mueller, Pharm.D., BCPS Clinical Specialist, Infectious Diseases Spartanburg Regional Medical Center LEARNING OBJECTIVES
More informationImmunization Update Dennis D. Stanley, BPharm Publix Pharmacy Vaccine and Travel Health Specialist
Immunization Update 2018 Dennis D. Stanley, BPharm Publix Pharmacy Vaccine and Travel Health Specialist Disclosures Merck speakers bureau Vaxserve speakers bureau Mrs. Jones shows up for her second ShingRix
More informationInfluenza Update. Lisa Grohskopf, MD, MPH Influenza Division, CDC. NAICP Call 6 October 2015
Influenza Update Lisa Grohskopf, MD, MPH Influenza Division, CDC NAICP Call 6 October 2015 National Center for Immunization and Respiratory Diseases Influenza Division Overview Surveillance update ACIP
More informationTalkin Flu Mid-America Immunization Coalition August 18, William Atkinson, MD, MPH Immunization Action Coalition
Talkin Flu Mid-America Immunization Coalition August 18, 2016 William Atkinson, MD, MPH Immunization Action Coalition Disclosures William Atkinson has worked as a consultant to Merck and as a speaker for
More informationImmunizations: An Overview. Sutter Health May 9, 2017 John Apostolo, PharmD, MBA Heidi Rens, PharmD
Immunizations: An Overview Sutter Health May 9, 2017 John Apostolo, PharmD, MBA Heidi Rens, PharmD Sutter Health: System Overview 2 Agenda Sutter Health Overview Sutter Health Vaccine overview Clinical
More informationMA Adult Immunization Coaltion Flu Update September 28, 2016
MA Adult Immunization Coaltion Flu Update September 28, 2016 Susan M. Lett, MD, MPH Medical Director, Immunization Program Division of Epidemiology and Immunization Massachusetts Department of Public Health
More informationNew Vaccine Schedules. Disclosure. Overview. Immunization Recommendations in Primary Care. Objectives Pharmacists. Objectives Pharmacy Technicians
Disclosure Immunization Recommendations in Primary Care I have nothing to disclose. Betsy Blake, PharmD, BCPS October 2017 Objectives Pharmacists Learning Objectives: At the completion of this activity,
More informationACIP Meeting Update, New Recommendations and Pending Influenza Season
ACIP Meeting Update, New Recommendations and Pending Influenza Season February 17 th 2011 www.immunizetexas.com ACIP Upcoming Agenda and New Recommendations ACIP (February 23-24 th 2011) Topics for meeting
More informationFlu Vaccine Access Via Pharmacy Vaccine Network
Re: Flu Vaccine Access Via Pharmacy Vaccine Network Effective 9/15/2016, IEHP Medi-Cal and Medicare DualChoice Cal MediConnect (IEHP Direct) Members who are over 18 years old may obtain Flu Vaccines through
More informationImmunization Update 2015
Immunization Update 2015 William Atkinson, MD, MPH Immunization Action Coalition Kentucky Immunization Conference Louisville, Kentucky October 14, 2015 Information in this presentation are valid as of
More informationHIT ME WITH YOUR BEST SHOT: UPDATE ON IMMUNIZATIONS. Karen Hoang, PharmD Clinical Pharmacy Specialist, MTM Services UPMC Health Plan
HIT ME WITH YOUR BEST SHOT: UPDATE ON IMMUNIZATIONS Karen Hoang, PharmD Clinical Pharmacy Specialist, MTM Services UPMC Health Plan DISCLOSURES No financial or other conflicts to disclose LEARNING OBJECTIVES
More information2/16/2015 IMMUNIZATION UPDATE Kelly Ridgway, RPh February 21, Today s Overview NEW RECOMMENDATIONS
IMMUNIZATION UPDATE 2015 Kelly Ridgway, RPh February 21, 2015 Today s Overview 1 2 3 4 5 6 Pneumococcal Vaccine Recommendations Meningococcal Vaccine Recommendations HPV Vaccine Recommendations Patient
More informationMeningococcal Update. Disclosure. Meningococal and Influenza Vaccines Update! Robert Wittler, MD Sept 12, 2014 KAAP Fall CME Meeting
1 Meningococal and Influenza Vaccines Update! Robert Wittler, MD Sept 12, 2014 KAAP Fall CME Meeting 2 Disclosure Speakers Bureau: Sanofi Pasteur Vaccines and Novartis! I do not intend to discuss an unapproved/
More informationInfluenza Prevention Update
Influenza Prevention Update Dean A. Blumberg, MD, FAAP Disclosure speakers bureau: sanofi pasteur, Merck Discussion off label use of FDA approved vaccines Influenza Prevention Update Seasonal influenza
More informationImmunization Update 2017
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Immunization Update 2017 Donna L. Weaver, RN, MN Nurse Educator Immunization Services Division Connecticut
More informationPreteen and teen vaccines: what to do with the recent recommendations
Preteen and teen vaccines: what to do with the recent recommendations MARK H. SAWYER UCSD SCHOOL OF MEDICINE RADY CHILDREN S HOSPITAL SAN DIEGO Continuing Education The Illinois Chapter, American Academy
More informationMDPH Influenza Update
Massachusetts Department of Public Health Bureau of Infectious Disease and Laboratory Sciences MDPH Influenza Update 9-27-2017 Susan M. Lett, MD, MPH Medical Director, Immunization Program MA Department
More informationDeanna Tran, PharmD, BCACP Assistant Professor Cherokee Layson-Wolf, PharmD, BCACP Associate Professor
Deanna Tran, PharmD, BCACP Assistant Professor dtran@rx.umaryland.edu Cherokee Layson-Wolf, PharmD, BCACP Associate Professor cwolf@rx.umaryland.edu Disclosures Deanna Tran declares no conflicts of interest,
More informationImmunization Update 2015
Immunization Update 2015 William Atkinson, MD, MPH* California Immunization Coalition Summit Riverside, California April 26, 2015 *Representing the Immunization Action Coalition, Saint Paul, MN Advisory
More informationACIP Recommendation Update. Mark H. Sawyer, MD UCSD School of Medicine Rady Children s Hospital San Diego
ACIP Recommendation Update Mark H. Sawyer, MD UCSD School of Medicine Rady Children s Hospital San Diego What has ACIP been up to lately? New Recommendations Tdap vaccination for each pregnancy Meningococcal
More information7/13/2016. Immunization Update Disclosures. Objectives. No financial disclosures to report
Immunization Update 2016 Courtney A. Robertson, PharmD Clinical Assistant Professor University of Louisiana at Monroe School of Pharmacy Disclosures No financial disclosures to report Objectives Pharmacists
More informationImmunization Update 2016
Immunization Update 2016 Stephan L. Foster, Pharm.D, FAPhA Professor University of Tennessee Jeff Goad, Pharm.D., M.P.H.,FAPhA Professor and Chair Chapman University 2 Disclosures Jeff Goad Speakers Bureau
More informationWhose Calling the Shots? - A 2019 Vaccine Update. Frank Bell Swedish Pediatric Infectious Disease Jan 2019
Whose Calling the Shots? - A 2019 Vaccine Update Frank Bell Swedish Pediatric Infectious Disease Jan 2019 2019 Vaccine Update Vaccines Meningococcal serogroup B HPV Pertussis Influenza Children with uncertain
More informationAdult Immunization Update 2015
Adult Immunization Update 2015 Objectives Upon completion of this session, the pharmacist should be able to: Compare and contrast previous versions of the ACIP immunization schedules with the most recent
More informationGuidelines for Vaccinating Pregnant Women
Guidelines for Vaccinating Pregnant Women March 2012 Guidelines for Vaccinating Pregnant Women Abstracted from recommendations of the Advisory Committee on Immunization Practices (ACIP) MARCH 2012 Risk
More informationGuidelines for Vaccinating Pregnant Women
Guidelines for Vaccinating Pregnant Women April 2013 Guidelines for Vaccinating Pregnant Women Abstracted from recommendations of the Advisory Committee on Immunization Practices (ACIP) April 2013 Risk
More informationPlatforms. Adolescent Immunization Update and the 16 Year Old Platform. Advisory Committee on Immunization Practices (ACIP)
Adolescent Immunization Update and the 16 Year Old Platform William Atkinson, MD, MPH Associate Director for Immunization Education Immunization Action Coalition Advisory Committee on Immunization Practices
More informationObjectives 1. Become familiar with current immunization schedules for children
Sarah Matches, DO, FAAP Assistant Professor UNTHSC, Dept. of Pediatrics Objectives 1. Become familiar with current immunization schedules for children 2. Describe the international progress in reducing
More informationImmunization Update 2018
Immunization Update 2018 Keri Hurley-Kim, PharmD, MPH Assistant Professor, Department of Pharmacy Practice West Coast University School of Pharmacy Conflicts of Interest Keri Hurley-Kim declares no conflicts
More informationNeedle Facts: Immunization Update 2016
Needle Facts: Immunization Update 2016 Miranda Wilhelm, Pharm.D. Clinical Associate Professor Southern Illinois University Edwardsville School of Pharmacy Disclosure / Conflict of Interest Miranda Wilhelm
More informationHot topics in immunization American Pharmacists Association
CPE Hot topics in immunization American Pharmacists Association Abstract Objectives: To describe recent changes in recommended immunization practices, including the introduction of new vaccines, and to
More informationNational Immunization Update
National Immunization Update H. Cody Meissner, M.D. Professor of Pediatrics Tufts Medical Center Boston, MA October 18, 2018 23 rd MIAP Immunization Conference Framingham, MA Disclaimers/Disclosure I have
More informationNational Immunization Update
National Immunization Update H. Cody Meissner, M.D. Professor of Pediatrics Tufts Medical Center Boston, MA October 18, 2018 23 rd MIAP Immunization Conference Framingham, MA Disclaimers/Disclosure I have
More informationDisclosures. Potential conflicts. No off-label use discussion. Safety Review Committee. Data and Safety Monitoring Board
2016 Vaccine Update Clinical Reviews Rochester, Minnesota November 2 and November 16, 2016 Robert M Jacobson, MD, FAAP Medical Director, Mayo Clinic Primary Care Immunization Program Disclosures Potential
More informationUpdate on Influenza Vaccines, the Influenza Season, and the Impact of Vaccination on Influenza Disease Burden
National Center for Immunization & Respiratory Diseases Update on Influenza Vaccines, the 2017 2018 Influenza Season, and the Impact of Vaccination on Influenza Disease Burden Melissa Rolfes, PhD MPH Epidemiologist
More informationImmunizations. Update Immunizations through Time. Learning Objectives. Presenter Disclosure Information. 10:30 11:45am. Immunization Update
10:30 11:45am Immunization Update SPEAKER John Russell, MD Presenter Disclosure Information The following relationships exist related to this presentation: John Russell, MD, serves on Speaker s Bureau
More informationACIP Update, 2014: Summary of February, 2014 Meeting
ACIP Update, 2014: Summary of February, 2014 Meeting Raymond A. Strikas, MD, MPH Immunization Services Division National Center for Immunization and Respiratory Diseases Centers for Disease Control and
More informationAdult Immunization Update April 2016
Adult Immunization Update April 2016 C. Wayne Weart, Pharm D, FASHP, FAPhA, BCPS Professor of Clinical Pharmacy and Outcome Sciences South Carolina College of Pharmacy Professor of Family Medicine Medical
More informationUpdate on Vaccine Recommendations. Objectives. Childhood Immunization Schedule At the Turn of the Century. New Horizons in Pediatrics April 30, 2017
Centers for for Disease Disease Control Control and and Prevention Prevention National Center for Immunization and Respiratory Diseases Update on Vaccine Recommendations New Horizons in Pediatrics April
More informationPREVENTIVE IMMUNIZATIONS. PREVENTIVE IMMUNIZATIONS These codes do not have a diagnosis code requirement for preventive benefits to apply.
An immunization that does not fall under one of the exclusions in the Certificate of Coverage is considered covered after the following conditions are satisfied: (1) FDA approval; (2) explicit ACIP recommendation
More informationNothing to disclose. Vaccinations for Adults and Adolescents: An Update. Key Resource
Vaccinations for Adults and Adolescents: An Update Nothing to disclose. Lisa G. Winston, MD Professor of Medicine, University of California, San Francisco Vice Chief, Inpatient Medical Services and Hospital
More informationVaccinations for Adults
Case: Vaccinations for Adults Lisa Winston, MD University of California, San Francisco San Francisco General Hospital A 30-year old healthy woman comes for a routine visit. She is recently married and
More informationThese slides are the property of the presenter. Do not duplicate without express written consent.
Cancer Survivorship Protecting Against Vaccine Preventable Diseases Heidi Loynes BSN, RN Immunization Nurse Educator Michigan Department of health and Human Services (MDHHS) loynesh@michigan.gov Are Vaccine-Preventable
More informationPREVENTIVE IMMUNIZATIONS. PREVENTIVE IMMUNIZATIONS These codes do not have a diagnosis code requirement for preventive benefits to apply.
An immunization that does not fall under one of the exclusions in the Certificate of Coverage is considered covered after the following conditions are satisfied: (1) FDA approval; (2) explicit ACIP recommendation
More informationImmunization Guidelines for the Use of State Supplied Vaccine May 17, 2015
DTaP / DT DTaP/IPV/Hep B Combination (Pediarix ) Children from 6 weeks of age up to the 7 th birthday Children from 2 months of age up to the 7th birthday: Indicated for the primary doses of DTaP, IPV,
More informationImmunizations June 5, Brenda Ormesher, MD Infectious Disease Peacehealth Medical Group Springfield, OR
Immunizations June 5, 2015 Brenda Ormesher, MD Infectious Disease Peacehealth Medical Group Springfield, OR Disclosures None Goals Understand basic public health impact of immunization Recognize types
More informationPennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10 13, 2016
Pennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10 13, 2016 Disclosures: Immunizations Donald Middleton, MD & Richard Zimmerman,
More informationInfluenza Clinical Bulletin # 3: October 8, 2009 Vaccination Guidelines for Patients for Influenza
The purpose of this document is to provide NYP providers with the most current recommendations regarding influenza vaccination for their patients. It is important to recognize that guidance reflects optimal
More informationWhat You Need to Know About the Flu
Wednesday, August 0, 017 BLUE P FISH E D I A T R I C S www.bluefishmd.com CYPRESS EDITION Biannual Newsletter In This Issue Find Out: Who should receive the flu vaccine? Who should NOT receive the flu
More informationWhat s New With Immunizations
What s New With Immunizations 2018 Annual Update COURTNEY A. ROBERTSON, PHARMD, BCPS CLINICAL ASSISTANT PROFESSOR UNIVERSITY OF LOUISIANA AT MONROE COLLEGE OF PHARMACY Disclosures No financial disclosures
More informationKenneth McCall, BSPharm, PharmD Associate Professor UNE President Maine Pharmacy Association
Kenneth McCall, BSPharm, PharmD Associate Professor UNE President Maine Pharmacy Association Objectives Discuss the gap between current rates and Healthy People 2020 goals for vaccinations. Categorize
More informationINFLUENZA UPDATE MCAAP Webinar Susan M. Lett, MD, MPH Medical Director, Immunization Program MA Department of Public Health
INFLUENZA UPDATE 2018-2019 MCAAP Webinar 11-15-18 Susan M. Lett, MD, MPH Medical Director, Immunization Program MA Department of Public Health Presenter Disclosure Information I, Susan Lett, have been
More information! Need to be extremely safe Even greater issue as disease prevalence wanes or uncommon diseases targeted
Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital! Need to be extremely safe Even greater issue as disease prevalence wanes or uncommon diseases targeted! Traditionally
More informationInfluenza: A recap of the season
Influenza: A recap of the 2012 2013 season March 22, 2013 Debra Blog MD, MPH Director Division of Epidemiology What are we going to talk about The 2012 13 Influenza Vaccine Influenza Activity and Surveillance
More informationImmunization Update 2013 Across the Lifespan
Immunization Update 2013 Across the Lifespan Andrew Kroger M.D., M.P.H. Medical Officer, Centers for Disease Control and Prevention New York State Association of County Health Officials (NYSACHO) New York
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXXIII NUMBER 4 September 2018 CONTAGIOUS COMMENTS Department of Epidemiology Influenza Vaccination Suchitra Rao, MBBS and Jason Child, PharmD New influenza vaccines have arrived. It is important
More informationVaccine Update Edition. Just the Essentials
Just the Essentials Presented By Michael A. Middleton, MD University of Florida - Pediatric Residency Medical College of Georgia Actively practicing at Middleton Pediatrics VaxCare s National Medical Director
More informationRecommended Immunization Schedules for Persons Aged 0 Through 18 Years UNITED STATES, 2016
Recommended Immunization Schedules for Persons Aged 0 Through 18 Years UNITED STATES, 2016 This schedule includes recommendations in effect as of January 1, 2016. Any dose not administered at the recommended
More informationImmunization Update 2017
Immunization Update 2017 Tamara Sheffield, MD, MPA, MPH November 10, 2017 DISCLOSURE: I have no conflicts of interest to disclose I will be discussing off label use I will be discussing an unlicensed vaccine
More information2015 ACIP Immunization Schedules & Recommendations and MDPH Updates
Massachusetts Department of Public Health Division of Epidemiology and Immunization 2015 ACIP Immunization Schedules & Recommendations and MDPH Updates Susan M. Lett, MD, MPH Medical Director, Immunization
More information3 rd dose. 3 rd or 4 th dose, see footnote 5. see footnote 13. for certain high-risk groups
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read
More informationACIP Meeting June 22, 2016 Influenza Session: Key Points
Update: CDC s Advisory Committee on Immunization Practices (ACIP) voted in favor of an interim recommendation that live attenuated influenza vaccine (LAIV), also known as the nasal spray flu vaccine, should
More informationACCREDITATION Pharmacy
FACULTY Michael D. Hogue, PharmD, FAPhA, FNAP Associate Dean, Center for Faith and Health Samford University College of Health Sciences Professor, Pharmacy Samford University McWhorter School of Pharmacy
More informationDisclosure Statement. Encapsulated Bacteria. Functions of the Spleen 10/25/2017. Pharmacist Learning Objectives
Pharmacist Learning Objectives No Spleen? No Problem. A Review of Vaccinations Indicated for the Asplenic Patient SCSHP Fall Meeting October 26, 2017 Explain the rationale for vaccinations in Select the
More informationAdult Immunization Update 2017 Including Influenza General Best Practice Guidelines for Immunization
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Adult Immunization Update 2017 Including Influenza General Best Practice Guidelines for Immunization
More informationJon Temte, MD/PhD Chair Wisconsin Council on Immunization Practices Professor of Family Medicine and Community Health
Jon Temte, MD/PhD Chair Wisconsin Council on Immunization Practices Professor of Family Medicine and Community Health University of Wisconsin School of Medicine and Public Health Grand Rounds September
More informationExpanding Practice of Pharmacist-Administered Immunizations for 2013
Expanding Practice of Pharmacist-Administered Immunizations for 2013 Rupal Mansukhani, PharmD Clinical Assistant Professor Rutgers University Piscataway, NJ Faculty Information Presenter: Rupal Mansukhani,
More informationIMMUNIZATION UPDATE: 2015 Patti Fabel, PharmD Clinical Assistant Professor SC College of Pharmacy USC Campus
IMMUNIZATION UPDATE: 2015 Patti Fabel, PharmD Clinical Assistant Professor SC College of Pharmacy USC Campus Learning Objectives - Pharmacists Advocate for patients receiving all recommended immunizations
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Routine Immunizations Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 3 References... 7 Effective Date... 4/15/2018
More informationAdult Vaccines in 2018: Where do we start?
Adult Vaccines in 2018: Where do we start? Jeff Goad, Pharm.D., MPH, FAPhA, FISTM Professor and Chair, Department of Pharmacy Practice Chapman University School of Pharmacy Annual Meeting San Francisco
More informationPreventative Vaccines. Vaccines for Special Populations. Vaccinations for Adults: An Update. Vaccines Generally Available in the U.S.
Vaccinations for Adults: An Update Preventative Vaccines Need to be extremely safe Even greater issue as disease prevalence wanes or uncommon diseases targeted Lisa G. Winston, MD University of California,
More information8/10/17 UPDATES IN ADOLESCENT AND ADULT IMMUNIZATIONS IN AMBULATORY CARE. Objectives. Background: ACIP. Membership. Focus
UPDATES IN ADOLESCENT AND ADULT IMMUNIZATIONS IN AMBULATORY CARE Laurie L. Duran, MSN, CRNP-Adult Texas Nurse Practitioners 29 th Annual Conference Sep 2017 Objectives 1. Use available resources to interpret
More information3/10/2017. Overview N.J.A.C. 8:57-6. Purpose of N.J.A.C. 8:57-6. New Jersey Higher Education Immunization Requirements
N.J.A.C. 8:57-6 New Jersey Higher Education Immunization Requirements Jenish Sudhakaran, MPH Population Assessment Coordinator Vaccine Preventable Disease Program New Jersey Department of Health NJCHA
More informationInfluenza Vaccines: Giving the Right Dose at the Right Time. Agenda
Influenza Vaccines: Giving the Right Dose at the Right Time Wednesday, December 9, 2015 12:00 PM ET Agenda Agenda Welcome and Introduction William Schaffner, MD, NFID Medical Director Influenza Vaccines:
More informationExperience with Quadrivalent Meningococcal Conjugate Vaccines (MenACWY) in Adolescent Vaccine Programs in the United States and Canada
Experience with Quadrivalent Meningococcal Conjugate Vaccines (MenACWY) in Adolescent Vaccine Programs in the United States and Canada Jessica MacNeil, MPH Epidemiologist Centers for Disease Control and
More informationVaccination Update. Pregnancy. 24-May-17. Disclosures. Overview. Paul Van Buynder Professor, Griffith University Chairman, Immunisation Coalition
Vaccination Update Paul Van Buynder Professor, Griffith University Chairman, Immunisation Coalition Disclosures I have been involved in vaccine studies funded by CSL, Sanofi Pasteur, Merck and Novartis
More information2007 ACIP Recommendations for Influenza Vaccine. Anthony Fiore, MD, MPH Influenza Division, NCIRD, CDC
2007 ACIP Recommendations for Influenza Vaccine Anthony Fiore, MD, MPH Influenza Division, NCIRD, CDC National Influenza Vaccine Summit April 19, 2007 Recommendation Changes for Influenza Vaccination:
More informationQuestions and Answers on Immunization Regulations Pertaining to Children Attending School/ Higher Education
New Jersey Department of Health (NJDOH), Vaccine Preventable Disease Program Questions and Answers on Immunization Regulations Pertaining to Children Attending School/ Higher Education Frequently Asked
More information9/11/2018. Influenza and Influenza Vaccines. Influenza. Influenza Virus. Highly infectious viral illness. First pandemic in 1580
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Influenza and Influenza Vaccines September 2018 Photographs and images included in this presentation
More informationInfluenza Backgrounder
Influenza Backgrounder Influenza Overview Influenza causes an average of 36,000 deaths and 200,000 hospitalizations in the U.S. every year. 1,2 Combined with pneumonia, influenza is the seventh leading
More informationFlu Vaccines for
This Clinical Resource gives subscribers additional insight related to the Recommendations published in October 2018 ~ Resource #341001 Flu Vaccines for 2018-2019 CDC has released recommendations for influenza
More informationVaccines, Not Just for Babies
Vaccines, Not Just for Babies Meg Fisher, MD Medical Director Disclosures I have no relevant financial relationships with the manufacturers of any commercial products or commercial services discussed in
More information